Shenzhen Syntheligo Biotech Unveils EuLV®: China's First Commercial Stable-Cell-Line-Based Lentiviral Vector Production System
WithCell Therapy TechnologyWith its continuous development, the potential and prospects of its clinical application are becoming increasingly evident; however, high production costs and complex manufacturing processes have become bottlenecks constraining its commercialization.To bring cell therapy products to market and benefit more patients, pharmaceutical companies must seekReducing Production Costs and Improving Production Efficiencyan effective approach.
The cost of cell therapy drugs mainly includes cell manufacturing, clinical trials, regulatory approval, and pharmaceutical company profits.. Among them,Cell Manufacturing as a Major Cost Component, with its cost directly determining the final price of the entire therapeutic drug. During the cell manufacturing process,Lentiviral VectorProduction accounts for a significant proportion. For instance, the production of lentiviral vectors via transient transfection of 293T cells constitutes 20%–30% of the manufacturing costs in cell therapy. However, this method is characterized by complex processes, low yield, inconsistent quality, and difficulties in scale-up.
To address this issue,ShenzhenShenyan Biotechnology Co., Ltd.(hereinafter referred to as “Shenyan Biotech”) by deeply optimizing molecular biology technologies such as gene editing and molecular switches,Design and Implementation of a High-Throughput Automated Cell Screening Workstation. Leveraging technologies such as big data analytics and bioinformatics, we have developed“EuLV® Lentiviral Vector Production System Based on Stable Cell Lines”。
On Wednesday, August 21 at 19:30, the 87th edition of VCBeat’s New Product Showcase will feature Liu Bin, Chief Marketing Officer of Shenyen Biotech, who will present“China’s First Lentiviral Vector Production System Based on Stable Cell Lines: EuLV®️”product promotion.
EuLV® System: Lentiviral Vectors Produced at Scale Using Stable Cell Lines
Resolved the urgent technical bottlenecks in the large-scale production of lentiviral vectors using a revolutionary new method, achieving large-scale production capacity comparable to existing manufacturing methods.100xtiter increase, which significantly enhances the production efficiency and product consistency of lentiviral vectors, reduces the manufacturing complexity of cell-based products, accelerates the development and market launch of cell therapies, while lowering production costsReduced by 80%The above.This technology is the first in the industry to achieve commercialization globally, representing an internationally leading and domestically pioneering product that fills a gap in China.
By deeply optimizing molecular biology techniques such as gene editing and molecular switches, we have designed and implemented a high-throughput automated cell screening workstation. Integrating big data analytics and bioinformatics, we are developing key technologies and core processes in the fields of cell therapy and gene therapy. This includes establishing systems for lentiviral vector production using stable cell lines, along with supporting end-to-end manufacturing processes for lentiviruses, thereby enhancing product safety and efficacy, reducing production costs, and expanding patient access.
It is of great significance to the development of China’s biopharmaceutical industry by fostering advances in cell therapy and gene therapy.
Scan the QR code on the poster to add the assistant and schedule a live stream appointment.
Liu Bin
Chief Marketing Officer, Shenyen Biotech
Graduated from The Hong Kong University of Science and Technology, with over 16 years of deep expertise in the life sciences sector. Previously contributed to and facilitated the R&D and Investigational New Drug (IND) applications for cell and gene therapy (CGT) products. Possesses extensive experience in business development, project management, product development, cGMP compliance, and IND submissions.
Currently responsible for formulating R&D and marketing strategies for CGT technologies and products at Shenyuan Biology, and conducting global business cooperation initiatives.
About Deep Research Biotech
Shenzhen Shenyan Biotechnology Co., Ltd., established in 2014, is a technology-driven enterprise dedicated to the research and development of core technologies and processes in the fields of gene therapy and cell therapy. The company is committed to discovering innovative pathways in life sciences through interdisciplinary integration and technological innovation involving computer science, electronic engineering, nanomaterials, chemical engineering, and other disciplines with life sciences. This approach accelerates the advancement of life science technologies and progressively addresses a series of key technical challenges in gene therapy, cell therapy, life sciences, and pharmaceutical R&D.
On the New Product Review by VCBeat
“Artery New Product Showcase” is a live-streaming program designed to support medical enterprises in launching their innovative products. The program’s mission is to facilitate the milestone launch of every innovative medical product. If your company has plans to release an innovative medical product or achieve a significant milestone and wishes to participate in the “Artery New Product Showcase,” please add our assistant for consultation.
Option 1: Watch the Live Stream via Mini Program
Scan the QR code below to contact the assistant and schedule a live stream (if already added, please proactively reach out to the assistant).
Method 2: Watch the live stream on the VCBeat app for a chance to win exciting prizes
Scan the QR code below to download the VCBeat app and register to watch the live stream.
Contact the assistant and send a screenshot of the live stream to enter the lucky draw for a chance to win a [15-day trial membership of VBInsight Industry Think Tank].
